Expanding applications of GLP-1 therapies: a careful view
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Effective weight loss strategies causing individuals to undergo significant weight loss often also cause a significant loss of fat-free mass”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [251]
In the citing paper
“Estimates from multiple clinical trials suggest that fat-free mass loss from GLP-1RA medications can be anywhere from 25 to 40% of the total weight loss”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [251]
Citations
Cites
Wilkinson, D. J., Piasecki, M., & Atherton, P. J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.005 · Cited by 874
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462 · cited 2×
“The long-term ef fi cacy in sustaining weight loss and delaying progression to type 2 diabetes in persons with both obesity and prediabetes, has been also recently documented by the 3-year safety and ef fi cacy outcomes with tirzepatide (SURMOUNT-1 trial) [2].”
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359
13. Older Adults: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s013 · Cited by 209
Muscle matters: The effects of medically induced weight loss on skeletal muscle
Prado, C. M., Phillips, S. M., Gonzalez, M. C., & Heymsfield, S. B. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00272-9 · Cited by 177 · cited 4×
“Ageing is also associated with fat in fi ltration of the muscle (myosteatosis) with lipotoxic effects, that can be detrimental to muscle strength and quality, affecting mobility function [3].”
InfluentialStrategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127 · cited 2×
“Additionally, mechanisms through which GLP-1-based therapies promote weight loss include appetite suppression [8].”
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
Hope, D. C. D., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01041-4 · Cited by 29
Anorexia of aging: An international assessment of healthcare providers' knowledge and practice gaps
Aprahamian, I., Coats, A. J. S., Morley, J. E., Klompenhouwer, T., Anker, S. D., & the International Advisory Board, A. R. A. B. F. N. A. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13355 · Cited by 27 · cited 1×
“Even in this case, some concerns can be argued in the older population because of the so-called “ anorexia of ageing ” which is a clear risk factor for malnutrition, sarcopenia, functional decline, and loss of independence [9].”
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.109 · Cited by 3 · cited 1×
“In this context, loss of muscle mass concomitant to weight loss and fat mass regain, have been associated with the so-called “ sarcopenic obesity ” , independently predicting morbidity and mortality in older adults [7].”
Cited by
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
Beyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 29
Azzolino, D., Gianturco, V., & Calvani, R. (2025) · Nutrients · doi:10.3390/nu17101727 · Cited by 1
“Excessive adipose tissue may further induce the release of pro-inflammatory mediators, which enhances muscle loss [11] and promotes the development of sarcopenic obesity, a condition associated with higher morbidity and mortality in older adults [12].”
Self-citationMcIntyre, C. C., O'Donnell, S. M., Lyday, R. G., Burdette, J. H., Cummings, S. R., Kritchevsky, S. B., & Laurienti, P. J. (2026) · Aging Cell · doi:10.1111/acel.70596 · Cited by 2
Metadata
- Authors
- Azzolino, D., & Lucchi, T.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Azzolino, Domenico
- Venue
- International Journal of Obesity
- Published
- 2025-04-16
- Volume
- 49
- Issue
- 7
- Pages
- 1207-1208
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4409487022
- Cited by
- 4
- References
- 10
- Citations by year
- 2026: 1 · 2025: 3
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- GLP-1 receptor agonists, obesity, type 2 diabetes prevention, prediabetes, weight loss, sarcopenia, fat-free mass loss, sarcopenic obesity, weight regain, body composition, older adults, frailty, resistance training, high-protein diet
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expanding applications of GLP-1 therapies: a careful view. https://app.cochat.ai/papers/10.1038/s41366-025-01788-4
- The paper
- Azzolino, D., & Lucchi, T. (2025). Expanding applications of GLP-1 therapies: a careful view. International Journal of Obesity. https://doi.org/10.1038/s41366-025-01788-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.